Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with adriamycin and cytoxan chemotherapy

Clinical Immunology

Volumn 101, Issue 3, 2001, Pages 303-314

  Zhou, Huanfang ^a   Sequeira, Manuel ^b   Goad, Mary E P ^a   Erickson, Jamie ^a   Wong, Anthony ^a   Clark, Ed ^a   Dunussi Joannopoulos, Kyriaki ^a   Li, Ronald C ^a   Friedrich, Stuart ^a   Hayes, Lori L ^a   Wolf, Stanley F ^a  

^a PFIZER INC   (United States)

^b Laboratory Animal Resources

Author keywords

Adjuvant therapy; Adriamycin; B7.2; B7.2 Ig; Costimulation; Cytoxan; Immunotherapy; Murine models; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; RECOMBINANT MURINE CD86 ANTIGEN IMMUNOGLOBULIN CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHRONOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GENE DELETION; HISTOPATHOLOGY; INFLAMMATION; LEUKEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SOLID TUMOR; T LYMPHOCYTE ACTIVATION;

EID: 0035207023     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2001.5123     Document Type: Article

References (17)

1. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant
2. The combination of chemotherapy and systemic immunotherapy with soluble B7-IgG leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses
3. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA- 4 costimulatory molecules
4. CD28/B7 costimulation: A review
5. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors
6. Tumor rejection after direct costimulation of cd8+ t cells by b7-transfected melanoma cells
7. Enhancement of antitumor immunity by ctla- 4 blockade
8. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells
9. Immune response enhancement by in vivo administration of B7.2Ig, a soluble costimulatory protein
10. + T- helper and a t-killer cell
11. Immunoregulation by Interleukin-12 in MB49.1 tumor-bearing mice: Cellular and cytokine-mediated effector mechanisms
12. In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties
13. Effectiveness of combined Interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: A liposome-mediated gene therapy treatment for bladder cancer
14. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2 transduced tumor cells
15. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA- 4
16. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using ctla- 4 blockade
17. Combination immunotherapy of B 16 melanoma using anti-cytotoxic t lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation